BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 06, 2010
 |  BC Week In Review  |  Company News  |  Other News

PDL BioPharma, Roche cancer, ophthalmic, inflammation news

PDL BioPharma said Roche's Genentech Inc. unit has paid the full sum of $73.8 million owed to PDL from 2Q10 sales of four antibody drug products: cancer drugs Avastin bevacizumab and Herceptin trastuzumab; ophthalmic drug Lucentis ranibizumab; and asthma drug

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >